Novo Nordisk Sees Mexico Ripe Market For Victoza Weight-Problem Drug
This article was originally published in PharmAsia News
Executive Summary
Eyeing an increasing problem of obesity in Mexico, Novo Nordisk has targeted the country as a potential market for its Victoza (liraglutide), filing for approval there at the same time it filed in the U.S.